Compare PCRX & UAMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | UAMY |
|---|---|---|
| Founded | 2006 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 955.8M |
| IPO Year | 2010 | 1997 |
| Metric | PCRX | UAMY |
|---|---|---|
| Price | $25.96 | $5.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $30.25 | $9.44 |
| AVG Volume (30 Days) | 479.1K | ★ 5.9M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | $39,257,708.00 |
| Revenue This Year | $6.78 | $219.89 |
| Revenue Next Year | $8.54 | $104.28 |
| P/E Ratio | $370.43 | ★ N/A |
| Revenue Growth | 26.04 | ★ 162.80 |
| 52 Week Low | $18.80 | $2.80 |
| 52 Week High | $27.64 | $19.71 |
| Indicator | PCRX | UAMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 34.32 |
| Support Level | $21.89 | $5.12 |
| Resistance Level | $26.94 | $8.28 |
| Average True Range (ATR) | 0.82 | 0.44 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 56.59 | 6.05 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.